Similar Articles |
|
The Motley Fool July 6, 2004 Alyce Lomax |
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them. |
The Motley Fool January 4, 2005 Seth Jayson |
Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship. |
The Motley Fool January 4, 2008 Timothy M. Otte |
Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December. |
The Motley Fool June 25, 2004 Steven Mallas |
Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio? |
The Motley Fool April 13, 2007 Ryan Fuhrmann |
Rite Aid's Right-Size Ambitions If the retail pharmacy chain can improve its net margins, reduce debt, and smoothly integrate its latest acquisition, the stock's upside would be substantial. |
The Motley Fool September 7, 2004 Seth Jayson |
Rejecting Rite Aid Shares of the drugstore chain droped 13%, and may prove to be a bargain if this is indeed a temporary slowdown and management can deliver more robust growth. |
The Motley Fool June 29, 2007 Ryan Fuhrmann |
Rite Aid's Recent Remedy Will increased market clout lead the drugstore operator to new highs? Investors, take note. |
The Motley Fool June 21, 2004 Seth Jayson |
Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore. |
The Motley Fool April 8, 2004 Seth Jayson |
Rite Aid Wrings Out Profits Net store closings and comps increases bring black ink to the pharmacy's bottom line. |
The Motley Fool January 5, 2004 Jeff Hwang |
Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales. |
The Motley Fool October 4, 2005 Seth Jayson |
Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space. |
The Motley Fool July 7, 2004 Steven Mallas |
CVS's Bright Picture Send CVS your digital photos over the Net, pick them up the next day. While competitors are sure to follow suit, this still shows how intellegent and creative this drugstore blue chip can be. |
The Motley Fool January 3, 2005 Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground. |
The Motley Fool March 8, 2005 Seth Jayson |
Rite Aid Wretched? Value investors may be interested in Rite Aid. |
The Motley Fool July 6, 2004 Steven Mallas |
Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%. |
The Motley Fool February 12, 2004 Dave Marino-Nachison |
CVS Bags Big 2003 A strong year for the drugstore giant has spilled into January. |
The Motley Fool January 5, 2007 Matthew Crews |
Rite Aid's Baby Steps If Rite Aid does manage 5% operating margins, this pharmacy chain's shares will get the love they deserve. |
The Motley Fool March 9, 2004 Alyce Lomax |
February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers. |
The Motley Fool December 11, 2006 Matthew Crews |
Rite Aid: Comps Mean Competition The pharmacy chain reported positive same-store results for November. Investors, take note. |
The Motley Fool June 2, 2004 Alyce Lomax |
Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine? |
The Motley Fool September 29, 2011 Navjot Kaur |
Should You Write Off Rite Aid? Rite Aid posts a relatively better quarter as wellness rewards the company. |
The Motley Fool June 27, 2011 Shubh Datta |
All Is Not Yet Right at Rite Aid Drug retailer Rite Aid posts losses in its first fiscal quarter and sees further losses ahead. |
The Motley Fool December 16, 2004 Nathan Slaughter |
Rx: Get Some Earnings Quick The No. 3 drug chain Rite Aid posts a sharp drop in earnings and slashes guidance again. |
The Motley Fool March 22, 2004 Alyce Lomax |
Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good. |
The Motley Fool June 10, 2004 Alyce Lomax |
Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition. |
The Motley Fool August 15, 2005 Bobby Shethia |
Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors. |
The Motley Fool September 27, 2004 Phil Wohl |
Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27. |
The Motley Fool September 29, 2011 Dan Caplinger |
Has Rite Aid Become the Perfect Stock? The company needs to turn itself around first before anyone will seriously expect superior results from Rite Aid. |
The Motley Fool June 11, 2007 Mike Cianciolo |
Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note. |
The Motley Fool November 23, 2008 Todd Wenning |
A Value Stock to Avoid in This Market Rite Aid is one "value" to avoid in this market. |
The Motley Fool September 27, 2007 Ryan Fuhrmann |
Rite Aid Looks a Little Peaked Bigger doesn't necessarily mean better for the drugstore retailer; it has quite a bit of work to do to convince investors it can successfully manage the empire that it has acquired. |
The Motley Fool March 24, 2004 Dave Marino-Nachison |
Eking Out an Eckerd Deal Investors are still waiting for a new leader to be crowned in the U.S. drugstore business. |
The Motley Fool September 26, 2007 Ryan Fuhrmann |
Foolish Forecast: Does Rite Aid Have the Right Rx? The retail pharmacy is set to release it second-quarter financial results. Investors, here is what you can expect to see. |
The Motley Fool August 19, 2011 Ilan Moscovitz |
Rite Aid Is Cheaper Than You Think Rite Aid tends to generate much more free cash flow than net income, suggesting that -- while things may not exactly be going swimmingly -- the company's stock might be a bit cheaper than many investors realize. |
The Motley Fool April 12, 2007 Ryan Fuhrmann |
Rite Aid Ekes Out a Gain: Fool by Numbers The drugstore retailer released fourth-quarter and year-end 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool September 25, 2009 Chris Jones |
The First Symptom of Health-Care Troubles? Rite Aid's problems imply bad news for consumers and the health-care system. |
The Motley Fool January 3, 2012 Shubh Datta |
Bright Spots for Rite Aid Better same-store sales help Rite Aid trim losses. |
The Motley Fool June 28, 2005 Mike Cianciolo |
Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever. |
The Motley Fool December 21, 2007 Timothy M. Otte |
Walgreen Shapes Up for 2008 The drugstore chain reports lower expenses in the first quarter while pumping up sales. |
The Motley Fool September 22, 2006 Ryan Fuhrmann |
More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note. |
The Motley Fool July 5, 2005 Alyce Lomax |
Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work. |
The Motley Fool April 11, 2008 Ryan Fuhrmann |
Rite Aid Hasn't Fully Recovered Rite Aid needs to be nursed back to health after its acquisition of Brooks Eckerd. |
The Motley Fool June 24, 2005 Stephen D. Simpson |
Is Rite Aid a Real Value Stock? Reality hasn't caught up with the company's turnaround prospects. Rite Aid must deal with a lot of debt and preferred equity if and when it recovers. |
The Motley Fool September 22, 2005 Stephen D. Simpson |
Rite Aid Not Right Yet The bleeding seems to have stopped at this pharmacy, but recovery could be a long and slow road. Intrepid, not to mention patient, investors may see potential here, but there are far better turnaround ideas to be had. |
The Motley Fool May 5, 2004 Mike Cianciolo |
CVS Prescribes Growth The soon-to-be leader of the drugstore market had a spectacular first quarter as a result of improved sales and margins, and CVS doesn't appear to be showing any signs of slowing down either, as the company continues to expand its business in both traditional and creative ways. |
The Motley Fool March 5, 2004 Dave Marino-Nachison |
Longs Coming Up Short Investors who bid on a Longs buyout haven't been rewarded in recent months. |
The Motley Fool September 22, 2010 Rich Smith |
Foolish Forecast: A Prescription for Rite Aid Investors Here's what you need to know before earnings come out tomorrow. |
The Motley Fool December 23, 2003 Dave Marino-Nachison |
Duane Reade's NY Story The well-known New York drugstore chain is going private after just under six years. |
The Motley Fool June 25, 2007 Ryan Fuhrmann |
Foolish Forecast: Rite Aid Aims for Healthy Growth The drugstore operator is set to report its first-quarter earnings. Investors, here is what you can expect to see. |
The Motley Fool February 4, 2005 Steven Mallas |
Walgreen's Wonderful Comps This drugstore chain doesn't need any medical attention. January comps prove it. |